ProgramBR101Target: BCMA/CD19
Disease settingRelapsed/refractory multiple myeloma
Product designIn Vivo CAR-T
PROPRIETARY PIPELINE
A focused pipeline.
One programmable-immunity strategy.
Byterna is advancing in vivo CAR-T, in vivo immunomodulation and personalized neoantigen cancer vaccines through a shared foundation of AI-enabled design, circular mRNA, analytics and integrated CMC and manufacturing. BR101 has a registered investigator-initiated trial in relapsed/refractory multiple myeloma (NCT07537049). Autoimmune diseases are presented separately as a preclinical development setting.
DiscoveryPreclinicalClinical
BR101In vivo CAR-T
BR202Personalized cancer vaccine
NEXTIn vivo mRNA options
Two therapeutic directions. One shared development system.
PORTFOLIO
Programs from
preclinical development to a registered IIT.
Current disease settings and development status are listed separately. Public descriptions intentionally exclude undisclosed targets and protocol thresholds.
ProgramDisease settingProduct designCurrent status
ProgramBR101Target: BCMA/CD19
Disease settingAutoimmune diseases
Product designIn Vivo CAR-T
Current statusPreclinical
ProgramBR102Target: Undisclosed
Disease settingAutoimmune diseases
Product designIn Vivo CAR-T
Current statusPreclinical
ProgramBR103Target: Undisclosed
Disease settingSolid Tumors
Product designIn Vivo CAR-T
Current statusPreclinical
ProgramBR201Target: Undisclosed
Disease settingSolid Tumors
Product designIn Vivo Immunomodulator
Current statusPreclinical
ProgramBR202Target: Patient-specific neoantigens
Disease settingPersonalized oncology
Product designPersonalized cancer vaccine
Current statusPreclinical
BR101 · Lead in vivo CAR-T program
A dual-target program with a registered investigator-initiated trial.
BR101 is a BCMA/CD19 circular mRNA program designed for transient, non-integrating immune-cell programming in vivo. It is being evaluated in a registered investigator-initiated trial in relapsed/refractory multiple myeloma (NCT07537049).
- Target
- BCMA/CD19
- Disease setting
- Relapsed/refractory multiple myeloma
- Product design
- In Vivo CAR-T
- Current status
- IIT
- Registry record
- NCT07537049 Source verified 16 September 2026
BR202 · Strategic personalized cancer vaccine program
From tumor profile to a manufacturable vaccine design.
BR202 is an AI-native personalized cancer vaccine program. Neodiscovery.ai predicts, ranks and optimizes multi-neoantigen combinations from each patient's tumor data. The selected antigen set informs circular mRNA construct design, while process and quality data establish a traceable path toward individualized manufacturing and release.
Explore Neodiscovery.ai ↗01
Patient & tumor inputsTumor-normal sequencing, expression and HLA context
02
AI combination designPredict, rank and optimize a multi-neoantigen set
03
Circular mRNA blueprintEncode the selected patient-specific antigen combination
04
Intelligent manufacturingConnect process parameters, quality data and release context
05
Evidence & feedbackBiological and manufacturing results update the next design
LEARN & UPDATEBiological evidence, process context and quality records inform the next design.